Enfortumab vedotin-ejfv (Intravenous)
Medically reviewed by Drugs.com. Last updated on Feb 9, 2022.
Warning: Serious Skin ReactionsEnfortumab vedotin-ejfv can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.Immediately withhold enfortumab vedotin-ejfv and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.Permanently discontinue enfortumab vedotin-ejfv in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions .
Commonly used brand name(s)
In the U.S.
- Padcev
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Enfortumab Vedotin
Uses for enfortumab vedotin-ejfv
Enfortumab vedotin-ejfv injection is used to treat urothelial cancer (bladder cancer) that has spread or cannot be removed by surgery in patients who have tried other cancer medicines (eg, immunotherapy medicine, platinum-containing cancer medicine) or in patients who are not able to receive a cancer medicine that contains cisplatin and have received one or more prior treatments.
Enfortumab vedotin-ejfv is to be given only by or under the supervision of your doctor.
Before using enfortumab vedotin-ejfv
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For enfortumab vedotin-ejfv, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to enfortumab vedotin-ejfv or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of enfortumab vedotin-ejfv injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of enfortumab vedotin-ejfv injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Interactions with food/tobacco/alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discu..
